

Stergios Boussios

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3598766/publications.pdf>

Version: 2024-02-01

70
papers

2,535
citations

159585

30
h-index

223800

46
g-index

70
all docs

70
docs citations

70
times ranked

2583
citing authors

#	ARTICLE	IF	CITATIONS
1	Non-Epithelial Ovarian Cancers: How Much Do We Really Know?. International Journal of Environmental Research and Public Health, 2022, 19, 1106.	2.6	46
2	Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet, The, 2022, 399, 447-460.	13.7	173
3	Systematic review of fetal and placental metastases among pregnant patients with cancer. Cancer Treatment Reviews, 2022, 104, 102356.	7.7	13
4	Case of cerebral venous thrombosis on a patient with background of nephrotic syndrome. BMJ Case Reports, 2022, 15, e248329.	0.5	1
5	Metastatic Anorectal Melanoma Presenting as Seizures: An Infrequent Culprit. Diseases (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlock 10	2.5	10
6	Epilepsy and Diagnostic Dilemmas: The Role of Language and Speech-Related Seizures. Journal of Personalized Medicine, 2022, 12, 647.	2.5	1
7	Androgen Receptor Gene Pathway Upregulation and Radiation Resistance in Oligometastatic Prostate Cancer. International Journal of Molecular Sciences, 2022, 23, 4786.	4.1	4
8	Applications of Proteomics in Ovarian Cancer: Dawn of a New Era. Proteomes, 2022, 10, 16.	3.5	66
9	Systematic review of the CUP trials characteristics and perspectives for next-generation studies. Cancer Treatment Reviews, 2022, 107, 102407.	7.7	13
10	Microsatellite instability testing in colorectal patients with Lynch syndrome: lessons learned from a case report and how to avoid such pitfalls. Personalized Medicine, 2022, 19, 277-286.	1.5	30
11	Epithelial Ovarian Cancer: Providing Evidence of Predisposition Genes. International Journal of Environmental Research and Public Health, 2022, 19, 8113.	2.6	48
12	COVID-19, Mucormycosis and Cancer: The Triple Threatâ€™ Hypothesis or Reality?. Journal of Personalized Medicine, 2022, 12, 1119.	2.5	5
13	Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer. International Journal of Environmental Research and Public Health, 2022, 19, 8577.	2.6	49
14	Chromosomal instability in cancers of unknown primary. European Journal of Cancer, 2022, 172, 323-325.	2.8	7
15	Management of Metastatic Spinal Cord Compression in Secondary Care: A Practice Reflection from Medway Maritime Hospital, Kent, UK. Journal of Personalized Medicine, 2021, 11, 110.	2.5	7
16	Melanoma of unknown primary: New perspectives for an old story. Critical Reviews in Oncology/Hematology, 2021, 158, 103208.	4.4	37
17	Immuno-oncology: a narrative review of gastrointestinal and hepatic toxicities. Annals of Translational Medicine, 2021, 9, 423-423.	1.7	6
18	Aberrations of DNA repair pathways in prostate cancer: a cornerstone of precision oncology. Expert Opinion on Therapeutic Targets, 2021, 25, 329-333.	3.4	39

#	ARTICLE	IF	CITATIONS
19	Genomic correlates of response and resistance to immune checkpoint inhibitors in carcinomas of unknown primary. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13583.	3.4	15
20	Cancer-Associated Thrombosis: A New Light on an Old Story. <i>Diseases (Basel, Switzerland)</i> , 2021, 9, 34.	2.5	8
21	Unraveling the Wide Spectrum of Melanoma Biomarkers. <i>Diagnostics</i> , 2021, 11, 1341.	2.6	55
22	Angiogenesis and Anti-Angiogenic Treatment in Prostate Cancer: Mechanisms of Action and Molecular Targets. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9926.	4.1	47
23	Genetic Aberrations of DNA Repair Pathways in Prostate Cancer: Translation to the Clinic. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9783.	4.1	35
24	The Experience of a Single NHS England Trust on the Impact of the COVID-19 Pandemic on Junior and Middle-Grade Doctors: What Is Next?. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 10413.	2.6	9
25	The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry. <i>Cancer Epidemiology</i> , 2021, 75, 102045.	1.9	35
26	BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12628.	4.1	44
27	Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach. <i>Investigational New Drugs</i> , 2020, 38, 181-193.	2.6	70
28	An Update on the Prognostic and Predictive Serum Biomarkers in Metastatic Prostate Cancer. <i>Diagnostics</i> , 2020, 10, 549.	2.6	34
29	Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond. <i>Drugs in R and D</i> , 2020, 20, 55-73.	2.2	84
30	New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 147, 102882.	4.4	42
31	Metformin and ovarian cancer: the evidence. <i>Annals of Translational Medicine</i> , 2020, 8, 1711-1711.	1.7	22
32	Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going?. <i>Annals of Translational Medicine</i> , 2020, 8, 1710-1710.	1.7	35
33	Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets—a narrative review. <i>Annals of Translational Medicine</i> , 2020, 8, 1712-1712.	1.7	36
34	NOTCH signalling in ovarian cancer angiogenesis. <i>Annals of Translational Medicine</i> , 2020, 8, 1705-1705.	1.7	24
35	Current and future immunotherapy approaches in ovarian cancer. <i>Annals of Translational Medicine</i> , 2020, 8, 1714-1714.	1.7	19
36	Narrative review on serous primary peritoneal carcinoma of unknown primary site: four questions to be answered. <i>Annals of Translational Medicine</i> , 2020, 8, 1709-1709.	1.7	7

#	ARTICLE	IF	CITATIONS
37	Ovarian cancer: state of the art and perspectives of clinical research. <i>Annals of Translational Medicine</i> , 2020, 8, 1702-1702.	1.7	2
38	Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?. <i>Annals of Translational Medicine</i> , 2020, 8, 1706-1706.	1.7	17
39	Systemic anti-cancer treatment in malignant ovarian germ cell tumours (MOGCTs): current management and promising approaches. <i>Annals of Translational Medicine</i> , 2020, 8, 1713-1713.	1.7	24
40	Wise Management of Ovarian Cancer: On the Cutting Edge. <i>Journal of Personalized Medicine</i> , 2020, 10, 41.	2.5	51
41	Upfront debulking surgery for high-grade serous ovarian carcinoma: current evidence. <i>Annals of Translational Medicine</i> , 2020, 8, 1707-1707.	1.7	8
42	Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review. <i>Diagnostics</i> , 2019, 9, 87.	2.6	94
43	PARP Inhibitors in Ovarian Cancer: The Route to "Elthaca". <i>Diagnostics</i> , 2019, 9, 55.	2.6	52
44	The Developing Story of Predictive Biomarkers in Colorectal Cancer. <i>Journal of Personalized Medicine</i> , 2019, 9, 12.	2.5	111
45	Ovarian carcinosarcoma: Current developments and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 134, 46-55.	4.4	42
46	Management of Recurrent Uterine Cervical Cancer. , 2019, , 191-214.		1
47	A review on pregnancy complicated by ovarian epithelial and non-epithelial malignant tumors: Diagnostic and therapeutic perspectives. <i>Journal of Advanced Research</i> , 2018, 12, 1-9.	9.5	37
48	Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives. <i>Annals of Gastroenterology</i> , 2018, 31, 659-669.	0.6	43
49	Extranodal diffuse large B-cell lymphomas: A retrospective case series and review of the literature. <i>Hematology Reports</i> , 2018, 10, 7070.	0.8	14
50	Spinal Ewing Sarcoma Debuting with Cord Compression: Have We Discovered the Thread of Ariadne?. <i>Anticancer Research</i> , 2018, 38, 5589-5597.	1.1	15
51	Metastatic Spinal Cord Compression: Unraveling the Diagnostic and Therapeutic Challenges. <i>Anticancer Research</i> , 2018, 38, 4987-4997.	1.1	63
52	Ovarian sex-cord stromal tumours and small cell tumours: Pathological, genetic and management aspects. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 120, 43-51.	4.4	42
53	Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 682-694.	27.6	86
54	The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer. <i>Clinical Oncology</i> , 2017, 29, 153-160.	1.4	67

#	ARTICLE	IF	CITATIONS
55	Current and future biomarkers in colorectal cancer. <i>Annals of Gastroenterology</i> , 2017, 30, 613-621.	0.6	88
56	Dynamics of Neutrophils-to-Lymphocyte Ratio Predict Outcomes of PD-1/PD-L1 Blockade. <i>BioMed Research International</i> , 2017, 2017, 1-5.	1.9	49
57	Primary Pulmonary Malignant Melanoma: Report of an Important Entity and Literature Review. <i>Case Reports in Oncological Medicine</i> , 2017, 2017, 1-9.	0.3	22
58	Managing Melanoma During Pregnancy. , 2016, , 123-134.		0
59	Pancreatic resection for renal cell carcinoma metastasis: An exceptionally rare coexistence. <i>International Journal of Surgery Case Reports</i> , 2016, 27, 198-201.	0.6	15
60	Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 108, 164-174.	4.4	134
61	Cancer specific risk in multiple sclerosis patients. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 29-34.	4.4	21
62	Non-epithelial Ovarian Cancer: Elucidating Uncommon Gynaecological Malignancies. <i>Anticancer Research</i> , 2016, 36, 5031-5042.	1.1	47
63	Systemic management of malignant ovarian germ cell tumors in older women: two case reports and a review of the literature. <i>Cancer Breaking News</i> , 2016, 4, 26-35.	0.0	0
64	Neuroendocrine Cell Carcinoma of Unknown Primary Arising in Long Standing History of Multiple Sclerosis. <i>Case Reports in Oncological Medicine</i> , 2015, 2015, 1-4.	0.3	1
65	Bleomycin-Induced Flagellate Erythema in a Patient Diagnosed with Ovarian Yolk Sac Tumor. <i>Case Reports in Oncological Medicine</i> , 2015, 2015, 1-2.	0.3	6
66	Malignant Ovarian Germ Cell Tumors in Postmenopausal Patients: The Royal Marsden Experience and Literature Review. <i>Anticancer Research</i> , 2015, 35, 6713-22.	1.1	27
67	Renal cell carcinoma in pregnancy: a rare coexistence. <i>Clinical and Translational Oncology</i> , 2014, 16, 122-127.	2.4	80
68	Lung cancer in pregnancy: Report of nine cases from an international collaborative study. <i>Lung Cancer</i> , 2013, 82, 499-505.	2.0	107
69	A narrative review of neoadjuvant, HIPEC and maintenance treatment in ovarian and peritoneal serous cancer: current status. <i>Gynecology and Pelvic Medicine</i> , 0, 3, 19-19.	0.1	3
70	Current evidences of BRCA mutations in genitourinary and gynecologic tumors: a scoping review. <i>Precision Cancer Medicine</i> , 0, .	1.8	0